Hanmi Financial's HM17321 Revolutionizes Obesity Treatment with Dual-Action Mechanism

Hanmi Pharm. Breaks Ground in Obesity Treatment with HM17321

Hanmi Pharm. Co., Ltd. makes significant strides in obesity management with the introduction of its innovative drug, HM17321, during the 2024 ObesityWeek conference in San Antonio, Texas. This groundbreaking treatment presents a dual-action mechanism that not only promotes fat loss but also enhances lean muscle mass—a notable improvement over existing GLP-1-based therapies that typically lead to muscle loss during weight reduction. Dr. In Young Choi, Head of Hanmi's R&D Center, asserts that HM17321 paves the way for a new paradigm in obesity treatment by effectively targeting the CRF2 receptor, distinguishing it from traditional incretin-based drugs.

Preclinical studies released at the conference reveal that HM17321 achieves weight loss levels comparable to semaglutide, a well-established GLP-1 therapy, while simultaneously preserving muscle mass. This is particularly important, as conventional obesity medications can result in a significant portion of weight loss—up to 40%—coming from muscle. Such loss can diminish metabolic rates and increase the likelihood of rapid weight regain after the cessation of treatment. By addressing these common drawbacks, Hanmi's HM17321 positions itself as a potential first-in-class obesity treatment that could change the landscape of weight management strategies.

In addition to HM17321, Hanmi Pharm. also presents findings on HM15275, a combination therapy aimed at further enhancing weight loss and muscle preservation. The company’s innovative approach, which incorporates advanced artificial intelligence and structural modeling, enhances the drug's efficacy in targeting the CRF2 receptor. As the obesity epidemic continues to grow, these advancements underscore Hanmi's commitment to developing effective therapies that not only facilitate weight loss but also improve overall quality of life for individuals struggling with obesity.

In tandem with the unveiling of HM17321, Hanmi Pharm. reinforces its dedication to obesity management through ongoing research and development. The introduction of HM15275 highlights the company’s strategic focus on combination therapies that can maximize the benefits of existing treatments, positioning Hanmi as a leader in the field. With a commitment to innovation and patient well-being, Hanmi is set to make a lasting impact on obesity treatment and management.